(Updated 4/17/16) On June 24, 2014, Ohr Pharmaceutical, Inc. announced positive top-line interim results for its Phase 2 clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD). The data demonstrated a positive benefit in multiple visual function including a gain in visual acuity of +10.4 letters with Squalamine eye [Read More]
Tag: eye drop
Antiangiogenic Drugs Are Stopping Neovascularization in Wet Macular Degeneration
(Updated 3/12/22) A substance in the body called Vascular Endothelial Growth Factor (VEGF) is responsible for the growth of new blood vessels. It promotes this growth by stimulating the endothelial cells, which form the walls of the vessels and transport nutrients and oxygen to the tissues. Evidence shows that when the retinal pigment epithelial (RPE) [Read More]
Summary of Research and Developments in Macular Degeneration: 2006-2007
by Dan Roberts This is a summary of all major research and developments pertinent to macular degeneration that occurred between mid-May 2006 and mid-May 2007. It is organized by month of occurence under the subsets “Pharmacology,” “Surgery,” “Nutrition” and/or “Miscellaneous.” The final section, “The Future,” summarizes work in progress that may lead to promising developments [Read More]